{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T20:11:32Z","timestamp":1777579892251,"version":"3.51.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Ensign Endowment for Gynecologic Cancer Research","award":["na"],"award-info":[{"award-number":["na"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Gynecol Obstet"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s00404-019-05104-0","type":"journal-article","created":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T09:28:53Z","timestamp":1551432533000},"page":"1641-1649","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy of pegylated liposomal doxorubicin maintenance therapy in platinum-sensitive recurrent epithelial ovarian cancer: a retrospective study"],"prefix":"10.1007","volume":"299","author":[{"given":"Erin A.","family":"Blake","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chrystal A.","family":"Bradley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sayedamin","family":"Mostofizadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franco M.","family":"Muggia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agustin A.","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynda D.","family":"Roman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6232-8701","authenticated-orcid":false,"given":"Koji","family":"Matsuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,3,1]]},"reference":[{"key":"5104_CR1","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1517\/13543784.2010.515585","volume":"19","author":"K Matsuo","year":"2010","unstructured":"Matsuo K, Lin YG, Roman LD et al (2010) Overcoming platinum resistance in ovarian carcinoma. Expert Opin Investig Drugs 19:1339\u20131354","journal-title":"Expert Opin Investig Drugs"},{"key":"5104_CR2","doi-asserted-by":"crossref","unstructured":"Mei L, Chen H, Wei DM et al. Maintenance chemotherapy for ovarian cancer. Cochrane Database Syst Rev. 2013:Cd007414","DOI":"10.1002\/14651858.CD007414.pub3"},{"key":"5104_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000094361","volume":"63","author":"PA DiSilvestro","year":"2007","unstructured":"DiSilvestro PA, Fisher M, Pearl ML et al (2007) Pilot phase 2 trial of 4\u00a0months of maintenance pegylated liposomal Doxorubicin in patients with advanced ovarian cancer after complete response to platinum and Paclitaxel-based chemotherapy. Gynecol Obstet Invest 63:1\u20136","journal-title":"Gynecol Obstet Invest"},{"key":"5104_CR4","doi-asserted-by":"publisher","first-page":"3798","DOI":"10.1200\/JCO.2010.33.5208","volume":"29","author":"JA Ledermann","year":"2011","unstructured":"Ledermann JA, Hackshaw A, Kaye S et al (2011) Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer. J Clin Oncol 29:3798\u20133804","journal-title":"J Clin Oncol"},{"key":"5104_CR5","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","volume":"365","author":"RA Burger","year":"2011","unstructured":"Burger RA, Brady MF, Bookman MA et al (2011) Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365:2473\u20132483","journal-title":"N Engl J Med"},{"key":"5104_CR6","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1093\/annonc\/mdl484","volume":"18","author":"E Andreopoulou","year":"2007","unstructured":"Andreopoulou E, Gaiotti D, Kim E et al (2007) Pegylated liposomal doxorubicin HCL (PLD; Caelyx\/Doxil): experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer. Ann Oncol 18:716\u2013721","journal-title":"Ann Oncol"},{"key":"5104_CR7","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1097\/IGC.0000000000001106","volume":"27","author":"J Giuliani","year":"2017","unstructured":"Giuliani J, Bonetti A (2017) The pharmacological costs of second-line treatments for recurrent ovarian cancer. Int J Gynecol Cancer. 27:1872\u20131876","journal-title":"Int J Gynecol Cancer."},{"key":"5104_CR8","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","volume":"30","author":"C Aghajanian","year":"2012","unstructured":"Aghajanian C, Blank SV, Goff BA et al (2012) OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 30:2039\u20132045","journal-title":"J Clin Oncol"},{"key":"5104_CR9","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ygyno.2015.08.004","volume":"139","author":"C Aghajanian","year":"2015","unstructured":"Aghajanian C, Goff B, Nycum LR et al (2015) Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer. Gynecol Oncol 139:10\u201316","journal-title":"Gynecol Oncol"},{"key":"5104_CR10","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","volume":"375","author":"MR Mirza","year":"2016","unstructured":"Mirza MR, Monk BJ, Herrstedt J et al (2016) Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med 375:2154\u20132164","journal-title":"N Engl J Med"},{"key":"5104_CR11","doi-asserted-by":"publisher","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","volume":"19","author":"AN Gordon","year":"2001","unstructured":"Gordon AN, Fleagle JT, Guthrie D et al (2001) Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19:3312\u20133322","journal-title":"J Clin Oncol"},{"key":"5104_CR12","doi-asserted-by":"publisher","first-page":"3323","DOI":"10.1200\/JCO.2009.25.7519","volume":"28","author":"E Pujade-Lauraine","year":"2010","unstructured":"Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E et al (2010) Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol 28:3323\u20133329","journal-title":"J Clin Oncol"},{"key":"5104_CR13","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/S0140-6736(15)01167-8","volume":"387","author":"JA Ledermann","year":"2016","unstructured":"Ledermann JA, Embleton AC, Raja F et al (2016) Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 387:1066\u20131074","journal-title":"Lancet"},{"key":"5104_CR14","doi-asserted-by":"crossref","unstructured":"Lawrie TA, Bryant A, Cameron A et al. Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer. Cochrane Database Syst Rev. 2013:Cd006910","DOI":"10.1002\/14651858.CD006910.pub2"},{"key":"5104_CR15","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1038\/bjc.2012.307","volume":"107","author":"U Wagner","year":"2012","unstructured":"Wagner U, Marth C, Largillier R et al (2012) Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients. Br J Cancer 107:588\u2013591","journal-title":"Br J Cancer"},{"key":"5104_CR16","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","volume":"335","author":"E Elm von","year":"2007","unstructured":"von Elm E, Altman DG, Egger M et al (2007) Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ 335:806\u2013808","journal-title":"BMJ"},{"key":"5104_CR17","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457\u2013481","journal-title":"J Am Stat Assoc"},{"key":"5104_CR18","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/S1470-2045(17)30279-6","volume":"18","author":"RL Coleman","year":"2017","unstructured":"Coleman RL, Brady MF, Herzog TJ et al (2017) Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology\/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 18:779\u2013791","journal-title":"Lancet Oncol."},{"key":"5104_CR19","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1200\/JCO.2011.36.9215","volume":"30","author":"SB Kaye","year":"2012","unstructured":"Kaye SB, Lubinski J, Matulonis U et al (2012) Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol 30:372\u2013379","journal-title":"J Clin Oncol"},{"key":"5104_CR20","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","volume":"18","author":"E Pujade-Lauraine","year":"2017","unstructured":"Pujade-Lauraine E, Ledermann JA, Selle F et al (2017) Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 18:1274\u20131284","journal-title":"Lancet Oncol."},{"key":"5104_CR21","doi-asserted-by":"publisher","first-page":"6159","DOI":"10.1158\/1078-0432.CCR-10-1027","volume":"16","author":"M Graeser","year":"2010","unstructured":"Graeser M, McCarthy A, Lord CJ et al (2010) A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res 16:6159\u20136168","journal-title":"Clin Cancer Res"},{"key":"5104_CR22","unstructured":"Barry W, Campos SM, Dizon DS et al (2018) Phase II study of pembrolizumab (pembro) combined with pegylated liposomal doxorubicin (PLD) for recurrent platinum-resistant ovarian, fallopian tube or peritoneal cancer. Gynecologic Oncology; 2018. 49thAnnual Meeting on Women\u2019s Cancer, New Orleans, LA March 24\u201327"},{"key":"5104_CR23","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1634\/theoncologist.2013-0021","volume":"18","author":"F Muggia","year":"2013","unstructured":"Muggia F (2013) Squamous cell carcinomas of the tongue and oral cavity as secondary malignancies: what factors are implicated? Oncologist. 18:245\u2013247","journal-title":"Oncologist."},{"key":"5104_CR24","doi-asserted-by":"crossref","unstructured":"Matsuo K, Blake EA, Yessaian AA, et al (2012) Long-term pegylated liposomal doxorubicin use and oromaxillary squamous cell carcinoma in endometrial cancer. Oncologist. United States, pp 1598\u20139","DOI":"10.1634\/theoncologist.2012-0358"},{"key":"5104_CR25","doi-asserted-by":"publisher","first-page":"3868","DOI":"10.1200\/JCO.2009.23.1183","volume":"27","author":"NJ Meropol","year":"2009","unstructured":"Meropol NJ, Schrag D, Smith TJ et al (2009) American Society of Clinical Oncology guidance statement: the cost of cancer care. J Clin Oncol 27:3868\u20133874","journal-title":"J Clin Oncol"},{"key":"5104_CR26","unstructured":"Wolford JE, Bai J, Eskander R, Hassef et al () Evaluating the cost-effectiveness of current FDA-approved PA2017RP inhibitors for the treatment of recurrent ovarian cancer. Journal of Clinical Oncology; 2017. American Society of Clinical Oncology Annual Meeting, Chicago, IL, June 2\u20136"},{"key":"5104_CR27","unstructured":"Dottino JA, Havrilesky LJ, Lu KH et al (2018) Are FDA-approved PARPi cost-effective as maintenance treatment of platinum-sensitive recurrent ovarian cancer? Gynecologic Oncology; 2018. 49th Annual Meeting on Women\u2019s Cancer, New Orleans, LA March 24\u201327"},{"key":"5104_CR28","unstructured":"Institute for Clinical and Economic Review (2017) Poly ADP-Ribose Polymerase (PARP) Inhibitors for Ovarian Cancer: Effectiveness and Value. Final Evidence Report. September 28"},{"key":"5104_CR29","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.ygyno.2016.03.005","volume":"141","author":"RD Alvarez","year":"2016","unstructured":"Alvarez RD, Matulonis UA, Herzog TJ et al (2016) Moving beyond the platinum sensitive\/resistant paradigm for patients with recurrent ovarian cancer. Gynecol Oncol 141:405\u2013409","journal-title":"Gynecol Oncol"},{"key":"5104_CR30","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","volume":"390","author":"RL Coleman","year":"2017","unstructured":"Coleman RL, Oza AM, Lorusso D et al (2017) Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390:1949\u20131961","journal-title":"Lancet"}],"container-title":["Archives of Gynecology and Obstetrics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-019-05104-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00404-019-05104-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-019-05104-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T21:56:16Z","timestamp":1663019776000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00404-019-05104-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,1]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["5104"],"URL":"https:\/\/doi.org\/10.1007\/s00404-019-05104-0","relation":{},"ISSN":["0932-0067","1432-0711"],"issn-type":[{"value":"0932-0067","type":"print"},{"value":"1432-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,1]]},"assertion":[{"value":"19 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Consultant, Tempus Labs (L.D.R.); honorarium, Chugai, book editorial, Springer, and meeting expense, OVAL (K.M.); none related to this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study involving human participants performed by authors is approved by Institutional Review Board, University of Southern California.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}